Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1990 1
1998 1
2002 1
2007 1
2009 1
2019 1
2020 5
2021 6
2022 5
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset.
Djebbari F, Rampotas A, Vallance G, Panitsas F, Basker N, Sangha G, Salhan B, Karim F, Al-Kaisi F, Gudger A, Ngu L, Poynton M, Lam HPJ, Morgan L, Yang L, Young J, Walker M, Tsagkaraki I, Anderson L, Chauhan SR, Maddams R, Soutar R, Triantafillou M, Prideaux S, Obeidalla A, Bygrave C, Basu S, Ramasamy K. Djebbari F, et al. Among authors: bygrave c. Hemasphere. 2022 May 26;6(6):e738. doi: 10.1097/HS9.0000000000000738. eCollection 2022 Jun. Hemasphere. 2022. PMID: 35651713 Free PMC article.
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial.
Royle KL, Coulson AB, Ramasamy K, Cairns DA, Hockaday A, Quezada S, Drayson M, Kaiser M, Owen R, Auner HW, Cook G, Meads D, Olivier C, Barnard L, Lambkin R, Paterson A, Dawkins B, Chapman M, Pratt G, Popat R, Jackson G, Bygrave C, Sive J, de Tute R, Chantry A, Parrish C, Cook M, Asher S, Yong K. Royle KL, et al. Among authors: bygrave c. BMJ Open. 2022 Nov 17;12(11):e063037. doi: 10.1136/bmjopen-2022-063037. BMJ Open. 2022. PMID: 36396306 Free PMC article.
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysis.
McMillan A, Basu S, Karunanithi K, Parkins E, Lau EYM, Cook G, Parrish C, Al-Kaisi F, Pratt G, Shafeek S, Jenkins S, Memon D, Bygrave C, Papanikolaou X, Maisel T, Hassan S, Moosai S, Chander G, Rakesh P, Kishore B, Karim F, Talbot G, Wandroo F, Yong K, Popat R. McMillan A, et al. Among authors: bygrave c. Br J Haematol. 2023 May;201(4):682-689. doi: 10.1111/bjh.18703. Epub 2023 Feb 23. Br J Haematol. 2023. PMID: 36822820
Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.
Djebbari F, Rampotas A, Vallance G, Panitsas F, Basker N, Sangha G, Salhan B, Karim F, Al-Kaisi F, Gudger A, Ngu L, Poynton M, Lam HPJ, Morgan L, Yang L, Young J, Walker M, Tsagkaraki I, Anderson L, Chauhan SR, Maddams R, Soutar R, Triantafillou M, Prideaux S, Obeidalla A, Eyre TA, Bygrave C, Kothari J, Basu S, Ramasamy K. Djebbari F, et al. Among authors: bygrave c. Br J Haematol. 2023 Apr;201(1):162-167. doi: 10.1111/bjh.18672. Epub 2023 Jan 31. Br J Haematol. 2023. PMID: 36720464 No abstract available.
High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
Khwaja J, Bomsztyk J, Mahmood S, Wisniowski B, Shah R, Tailor A, Yong K, Popat R, Rabin N, Kyriakou C, Sive J, Esposti SD, Larkin DFP, Worthington S, Hart A, Dowling E, Correia N, Bygrave C, Rydzewski A, Jamroziak K, Wechalekar AD. Khwaja J, et al. Among authors: bygrave c. Blood Cancer J. 2022 Sep 5;12(9):128. doi: 10.1038/s41408-022-00717-2. Blood Cancer J. 2022. PMID: 36064540 Free PMC article. No abstract available.
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial.
Camilleri M, Sive J, Wilson W, Pang G, Jenner R, Phillips E, Popat R, Ramasamy K, Bygrave C, Dadaga T, Streetly M, Cavenagh J, Chapman M, Barrington S, Pike L, Owen R, Clifton-Hadley L, Yong K. Camilleri M, et al. Among authors: bygrave c. Br J Haematol. 2021 Jan;192(1):e14-e16. doi: 10.1111/bjh.17168. Epub 2020 Nov 21. Br J Haematol. 2021. PMID: 33222153 Free PMC article. Clinical Trial. No abstract available.
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Camilleri M, Cuadrado M, Phillips E, Wilson W, Jenner R, Pang G, Kamora S, Streetly M, Popat R, Bygrave C, Owen R, Cavenagh J, Chapman M, Sive J, Eccersley L, Sheaff M, Benjamin R, Ramasamy K, Cook G, Virchis A, Chavda SJ, Clifton-Hadley L, Scully MA, Yong K. Camilleri M, et al. Among authors: bygrave c. Br J Haematol. 2021 May;193(4):750-760. doi: 10.1111/bjh.17377. Epub 2021 Mar 1. Br J Haematol. 2021. PMID: 33650100 Clinical Trial.
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.
Yong K, Wilson W, de Tute RM, Camilleri M, Ramasamy K, Streetly M, Sive J, Bygrave CA, Benjamin R, Chapman M, Chavda SJ, Phillips EH, Del Mar Cuadrado M, Pang G, Jenner R, Dadaga T, Kamora S, Cavenagh J, Clifton-Hadley L, Owen RG, Popat R. Yong K, et al. Among authors: bygrave ca. Lancet Haematol. 2023 Feb;10(2):e93-e106. doi: 10.1016/S2352-3026(22)00350-7. Epub 2022 Dec 15. Lancet Haematol. 2023. PMID: 36529145 Free article. Clinical Trial.
Risk of relapse of multiple myeloma following kidney transplantation.
Shah S, Ibrahim M, Delaney M, Schey S, Bygrave C, Streetly M, Benjamin R. Shah S, et al. Among authors: bygrave c. Clin Kidney J. 2019 Jan 25;12(2):216-223. doi: 10.1093/ckj/sfy137. eCollection 2019 Apr. Clin Kidney J. 2019. PMID: 30976399 Free PMC article.
Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
Khwaja J, Bomsztyk J, Atta M, Bygrave C, Forbes A, Durairaj S, Fernandes S, Taylor J, Paterson P, Brearton G, Crawley C, Sheehy O, Brown R, Soutar R, Garg M, Rydzewski A, Jamroziak K, Mahmood S, Wechalekar AD. Khwaja J, et al. Among authors: bygrave c. Br J Haematol. 2024 Jan 3. doi: 10.1111/bjh.19286. Online ahead of print. Br J Haematol. 2024. PMID: 38171355
23 results